LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-25. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
In the United States, religious justifications were first developed in the 19th century and are primarily supported by protestants who believe in dispensationalism. The watchdog group Military Religious Freedom Foundation disclosed they were told that the war was a part of God's plan, and that some military commanders have compared the war to the end times, especially Armageddon, an event in which Jesus returns in what is known as the second coming and is mentioned in the Book of Revelation. One officer complained that he was told by a commander that Donald Trump was anointed by Jesus. Some US politicians are calling for investigations of this. One of the major original complainants of this was himself a Christian. However, the allegations are still unverified. Pete Hegseth, attending a Christian worship service, prayed for there to be "overwhelming violence of action against those who deserve no mercy." This was later met with rebuke by Pope Leo XIV, condemning those who wage war and have "hands full of blood" and stating that God "does not listen to the prayers of those who wage war, but rejects them." On 6 April 2026, Trump asserted that God supports the US–Israeli war on Iran "because God is good, and God wants to see people taken care of." Hegseth, meanwhile, likened the US F-15E rescue operation in Iran to the resurrection of Jesus, stating that the missing airman was rescued from Iranian territory on Easter Sunday.
== Structures involved in clinical attachment loss == Clinical attachment loss refers to the apical migration and destruction of the tissues that secure the tooth within the periodontium. This process involves the coordinated breakdown of epithelial, connective tissue, and osseous components that collectively form the periodontal attachment apparatus.
is the area of the surface on contact. Pressure is a scalar quantity. It relates the vector area element (a vector normal to the surface) with the normal force acting on it. The pressure is the scalar proportionality constant that relates these two normal vectors:
=== Prisoner exchange === Following the ceasefire on 18 July 2025, a prisoner exchange attempt on 20 July 2025 in the Umm al-Zaytoun town failed after a shelling from northern Suwayda, according to the Syrian Observatory for Human Rights.
Sources: en.wikipedia.org
==== Encoded combinatorial libraries ==== When dealing with a non-peptide organic libraries library, it is not as simple to determine the identity of the content of a bead as in the case of a peptide one. In order to circumvent this difficulty, methods have been developed to attach molecules that encode the structure of the compound formed in the bead to the beads, in parallel with the synthesis of the library. Ohlmeyer and his colleagues published a binary encoding method. They used mixtures of 18 tagging molecules that, after cleaving them from the beads, could be identified by Electron Capture Gas Chromatography. Sarkar et al. describe chiral oligomers of pentenoic amides (COPAs) that can be used to construct mass encoded OBOC libraries. Kerr et al. introduced an innovative encoding method. An orthogonally protected removable bifunctional linker was attached to the beads. One end of the linker was used to attach the non-natural building blocks of the library, while encoding amino acid triplets were linked to the other end. The building blocks were non-natural amino acids and the series of their encoding amino acid triplets could be determined by Edman degradation. The important aspect of this kind of encoding was the possibility to cleave down from the beads the library members together with their attached encoding tags forming a soluble library. The same approach was used by Nikolajev et al. for encoding with peptides. In 1992, Brenner and Lerner introduced DNA sequences to encode the beads of the solid support that proved to be the most successful encoding method.
== Overdose == In overdose, phenibut can cause severe drowsiness, nausea, vomiting, eosinophilia, lowered blood pressure, renal impairment, and, above 7 grams, fatty liver degeneration. There are no specific antidotes for phenibut overdose. Lethargy, somnolence, agitation, delirium, tonic–clonic seizures, reduced consciousness or unconsciousness, and unresponsiveness have been reported in recreational users who have overdosed. Management of phenibut overdose includes activated charcoal, gastric lavage, induction of vomiting, and symptom-based treatment. There have been three associated deaths which found Phenibut in the users system but only one of these cases solely included Phenibut.
=== Celiac disease === In response to gluten, people with celiac disease will release gluten exorphins as part of the allergic immune response. Due to the weakening of intestinal walls caused by celiac disease, some of these gluten exorphins can make their way through the lining of the intestines and are then absorbed into the bloodstream.
Sources: en.wikipedia.org
After the great success in the United States, the incandescent light bulb patented by Edison also began to gain widespread popularity in Europe; among other places, the first Edison light bulbs in the Nordic countries were installed at the weaving hall of the Finlayson's textile factory in Tampere, Finland in March 1882. On 4 March 1880, just five months after Edison's light bulb, Alessandro Cruto developed a process to create thin carbon filaments by heating thin platinum filaments in the presence of gaseous ethyl alcohol to coat them with pure graphite, and then sublimating the platinum at high temperatures. In 1882 at the Munich Electrical Exhibition in Bavaria, Germany Cruto demonstrated bulbs that were more efficient than Edison's and produced a better, whiter light. Lewis Latimer, employed at the time by the United States Electric Lighting Company, developed an improved method of heat-treating carbon filaments which reduced breakage and allowed them to be molded into novel shapes, such as the characteristic "M" shape of Maxim filaments. On 17 January 1882, Latimer received a patent for the "Process of Manufacturing Carbons", an improved method for the production of light bulb filaments, which was purchased by the United States Electric Light Company. Latimer patented other improvements such as a better way of attaching filaments to their wire supports. In Britain, the Edison and Swan companies merged into the Edison and Swan United Electric Company (later known as Ediswan, and ultimately incorporated into Thorn Lighting Limited).
== Protein structure and Terminology == Proteins are chains of amino acids joined together by peptide bonds. Many conformations of this chain are possible due to the rotation of the main chain about the two torsion angles φ and ψ at the Cα atom. This conformational flexibility is responsible for differences in the three-dimensional structure of proteins.
In Euclidean geometry, a tangential quadrilateral (sometimes just tangent quadrilateral) or circumscribed quadrilateral is a convex quadrilateral whose sides all can be tangent to a single circle within the quadrilateral. This circle is called the incircle of the quadrilateral or its inscribed circle, its center is the incenter and its radius is called the inradius. Since these quadrilaterals can be drawn surrounding or circumscribing their incircles, they have also been called circumscribable quadrilaterals, circumscribing quadrilaterals, and circumscriptible quadrilaterals. Tangential quadrilaterals are a special case of tangential polygons. Other less frequently used names for this class of quadrilaterals are inscriptable quadrilateral, inscriptible quadrilateral, inscribable quadrilateral, circumcyclic quadrilateral, and co-cyclic quadrilateral. Due to the risk of confusion with a quadrilateral that has a circumcircle, which is called a cyclic quadrilateral or inscribed quadrilateral, it is preferable not to use any of the last five names. All triangles can have an incircle, but not all quadrilaterals do. An example of a quadrilateral that cannot be tangential is a non-square rectangle. The section characterizations below states what necessary and sufficient conditions a quadrilateral must satisfy to be able to have an incircle.
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are enzyme inhibitors that inhibit the enzyme dipeptidyl peptidase-4 (DPP-4). They are used in the treatment of type 2 diabetes mellitus. Inhibition of the DPP-4 enzyme prolongs and enhances the activity of incretins that play an important role in insulin secretion and blood glucose control regulation. Type 2 diabetes mellitus is a chronic metabolic disease that results from inability of the β-cells in the pancreas to secrete sufficient amounts of insulin to meet the body's needs. Insulin resistance and increased hepatic glucose production can also play a role by increasing the body's demand for insulin. Current treatments, other than insulin supplementation, are sometimes not sufficient to achieve control and may cause undesirable side effects, such as weight gain and hypoglycemia. In recent years, new drugs have been developed, based on continuing research into the mechanism of insulin production and regulation of the metabolism of sugar in the body. The enzyme DPP-4 has been found to play a significant role.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.